```
=> d his

     (FILE 'HOME' ENTERED AT 12:36:03 ON 27 JUN 2000)

     FILE 'REGISTRY' ENTERED AT 12:36:18 ON 27 JUN 2000
L1             STR
L2           4 S L1
L3         114 S L1 FUL

     FILE 'CAPLUS' ENTERED AT 12:37:45 ON 27 JUN 2000
L4          18 S L3

     FILE 'REGISTRY' ENTERED AT 12:37:51 ON 27 JUN 2000
L5           5 S L3 AND OC5-C6/ES
L6          19 S L3 AND OC5/ESS
L7             STR L1
L8             STR L1

     FILE 'CAPLUS' ENTERED AT 12:41:58 ON 27 JUN 2000

     FILE 'REGISTRY' ENTERED AT 12:42:09 ON 27 JUN 2000
L9           8 S L7 OR L8 SSS FUL SUB=L3
L10         22 S L5 OR L6 OR L9

     FILE 'CAPLUS' ENTERED AT 12:43:21 ON 27 JUN 2000
L11          1 S L10

     FILE 'CAOLD' ENTERED AT 12:44:17 ON 27 JUN 2000
L12          0 S L10

     FILE 'BEILSTEIN' ENTERED AT 12:44:29 ON 27 JUN 2000
L13         24 S L1 FUL
L14            STR
L15            STR
L16            STR
L17          0 S L14 OR L15 OR L16 OR L7 OR L8 SSS FUL SUB=L13
```

22 compounds

1 cite caplus

Ø cites Caold

Ø compounds

=> d que l11

L1 STR



Parent Search

REP G1=(0-1) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 9

STEREO ATTRIBUTES: NONE
L3 114 SEA FILE=REGISTRY SSS FUL L1
L5 5 SEA FILE=REGISTRY ABB=ON PLU=ON L3 AND OC5-C6/ES
L6 19 SEA FILE=REGISTRY ABB=ON PLU=ON L3 AND OC5/ESS
L7 STR



Subset 220 1 of 2

NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE
L8 STR



Subset 2 of 2

NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE

L9	8	SEA FILE=REGISTRY SUB=L3 SSS FUL L7 OR L8
L10	22	SEA FILE=REGISTRY ABB=ON PLU=ON L5 OR L6 OR L9
L11	1	SEA FILE=CAPLUS ABB=ON PLU=ON L10

=> d bib abs hitstr

L11 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2000 ACS
AN 2000:117059 CAPLUS
DN 132:171119
TI Water-soluble prodrugs of hindered alcohols or phenols
IN Stella, Valentino J.; Zygmunt, Jan J.; Georg, Ingrid Gunda; Safadi, Muhammed S.
PA University of Kansas, USA
SO PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000008033	A1	20000217	WO 1999-US17779	19990806

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1998-131385 19980807
OS MARPAT 132:171119
AB Water-sol. phosphonooxymethyl esters of drugs contg. aliph. or arom. hindered OH groups are prepd. as prodrugs to improve the bioavailability of the drugs without use of surfactants which lead to severe side effects.
Among the drugs thus rendered water sol. are camptothecin, propofol, cyclosporin A, etoposide, and .alpha.-tocopherol. Thus, propofol was converted via its O-(methylthio)methyl, O-chloromethyl, and O-phosphonooxymethyl dibenzyl ester derivs. to O-phosphonooxymethylpropofol. This compd. had a water soly. of .apprx.500 mg/mL, was nontoxic in rats, was converted to propofol by alk. phosphatase
in vitro, and produced anesthesia in dogs in a similar manner to a com. propofol formulation (Diprivan).
IT **258516-91-5P 258516-93-7P 258516-95-9P**
258516-97-1P 258516-99-3P 258517-01-0P
258517-02-1P 258517-03-2P 258517-04-3P
258517-05-4P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(water-sol. prodrugs of hindered alcs. or phenols)
RN 258516-91-5 CAPLUS
CN Methanol, [[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl]oxy]-, dihydrogen phosphate (9CI) (CA INDEX NAME)



RN 258516-93-7 CAPLUS
CN Methanol, [[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl]oxy]-, dihydrogen phosphate, disodium salt (9CI) (CA INDEX NAME)



● 2 Na

RN 258516-95-9 CAPLUS
CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-[(phosphonooxy)methoxy]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258516-97-1 CAPLUS
CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-[(phosphonooxy)methoxy]-, disodium salt, (4S)- (9CI) (CA INDEX NAME)

Searched by John Dantzma 703-308-4488

Absolute stereochemistry.



● 2 Na

RN 258516-99-3 CAPLUS
CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-[(phosphonooxy)methoxy]-, monosodium salt, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 258517-01-0 CAPLUS
CN L-Lysine, compd. with (4S)-4-ethyl-4-[(phosphonooxy)methoxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 258516-95-9

CMF C21 H19 N2 O8 P

Absolute stereochemistry.



CM 2

CRN 56-87-1
CMF C6 H14 N2 O2
CDES 5:L

Absolute stereochemistry.



RN 258517-02-1 CAPLUS
CN L-Arginine, compd. with (4S)-4-ethyl-4-[(phosphonooxy)methoxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 258516-95-9
CMF C21 H19 N2 O8 P

Absolute stereochemistry.



CM 2

CRN 74-79-3
CMF C6 H14 N4 O2
CDES 5:L

Absolute stereochemistry.



RN 258517-03-2 CAPLUS
CN D-Glucitol, 1-deoxy-1-(methylamino)-, compd. with (4S)-4-ethyl-4-[(phosphonooxy)methoxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 258516-95-9
CMF C21 H19 N2 O8 P

Absolute stereochemistry.



CM 2

CRN 6284-40-8
CMF C7 H17 N O5
CDES *

Absolute stereochemistry.



RN 258517-04-3 CAPLUS
CN Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5-[3,5-dimethoxy-4-[(phosphonooxy)methoxy]phenyl]-9-[[4,6-O-(1R)-ethylidene-.beta.-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-, (5R,5aR,8aR,9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258517-05-4 CAPLUS
CN Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5-[3,5-dimethoxy-4-[(phosphonooxy)methoxy]phenyl]-9-[[4,6-O-(1R)-ethylidene-.beta.-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-, disodium salt, (5R,5aR,8aR,9S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 Na

Searched by John Dantzma 703-308-4488

IT **258516-36-8P 258516-40-4P 258516-48-2P**
258516-51-7P 258516-55-1P 258516-58-4P
258516-64-2P 258516-67-5P 258516-69-7P
258516-72-2P 258516-78-8P 258516-80-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(water-sol. prodrugs of hindered alcs. or phenols)

RN 258516-36-8 CAPLUS

CN Phosphoric acid, [[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl]oxy]methyl bis(phenylmethyl) ester
(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— $(CH_2)_3$ — $CHMe_2$

RN 258516-40-4 CAPLUS

CN Phosphoric acid, 4-[(5R,5aR,8aR,9S)-9-[[4,6-O-(1R)-ethylidene-.beta.-D-glucopyranosyl]oxy]-5,5a,6,8,8a,9-hexahydro-6-oxofuro[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-5-yl]-2,6-dimethoxyphenyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 258516-48-2 CAPLUS
CN Phosphoric acid, [[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl]oxy]methyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258516-51-7 CAPLUS
CN Phosphoric acid, [2,6-bis(1-methylethyl)phenoxy]methyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 258516-55-1 CAPLUS
CN Phosphoric acid, [[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl]oxy]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— $CHMe_2$

RN 258516-58-4 CAPLUS
CN Phosphoric acid, bis(1,1-dimethylethyl) 4-[(5R,5aR,8aR,9S)-9-[[4,6-O-(1R)-ethylidene-.beta.-D-glucopyranosyl]oxy]-5,5a,6,8,8a,9-hexahydro-6-oxofuro[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-5-yl]-2,6-dimethoxyphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 258516-64-2 CAPLUS
CN Phosphoric acid, bis(1,1-dimethylethyl) [[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl]oxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258516-67-5 CAPLUS
CN Phosphoric acid, [2,6-bis(1-methylethyl)phenoxy]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 258516-69-7 CAPLUS
CN Phosphoric acid, [[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl]oxy]methyl di-2-propenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— $(CH_2)_3-CHMe_2$

RN 258516-72-2 CAPLUS
CN Phosphoric acid, 4-[(5R,5aR,8aR,9S)-9-[[4,6-O-(1R)-ethylidene-.beta.-D-glucopyranosyl]oxy]-5,5a,6,8,8a,9-hexahydro-6-oxofuro[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-5-yl]-2,6-dimethoxyphenyl di-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 258516-78-8 CAPLUS
CN Phosphoric acid, [[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl]oxy]methyl di-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258516-80-2 CAPLUS
CN Phosphoric acid, [2,6-bis(1-methylethyl)phenoxy]methyl di-2-propenyl ester
(9CI) (CA INDEX NAME)



RE.CNT 5
RE
(1) Bristol-Myers Squibb Co; EP 0604910 A 1994
(2) Bristol-Myers Squibb Co; EP 0639577 A 1995
(3) Bristol-Myers Squibb Co; EP 0747385 A 1996
(4) Golik, J; BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 1996, V6(15), P1837 CAPLUS
(5) Safadi, M; PHARMACEUTICAL RESEARCH 1993, V10(9), P1350 CAPLUS

=> d que stat l17

L1 STR



REP G1=(0-1) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 9

STEREO ATTRIBUTES: NONE
L7 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE
L8 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE
L13 24 SEA FILE=BEILSTEIN SSS FUL L1
L14 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE
L15 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE
L16 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE
L17 0 SEA FILE=BEILSTEIN SUB=L13 SSS FUL L14 OR L15 OR L16 OR L7 OR L8

100.0% PROCESSED 8 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.09